Purpose: To report the long-term (>5 years) results of full macular translocation in patients with choroidal neovascularization (CNV). Design: A retrospective, interventional case series. Methods: This study involved 32 eyes of 32 patients who had undergone full macular translocation for CNV. The median follow-up was 6.5 (range, 5.2-7.7) years. We evaluated the best corrected visual acuity, fundus examinations before, 1 year, and 5 years after operation, and postoperative complications. Results: At the 1-year follow-up, foveal retinal pigment epithelium (RPE) atrophy was observed in only 3 eyes (12%), and the mean logarithm of the minimum angle of resolution (logMAR) at that time (1.39±0.67) was not significantly changed from that before operation (logMAR, 1.31±0.66) in 25 eyes with age-related macular degeneration (AMD). However, at 5-year follow-up, foveal RPE atrophy increased (18 eyes, 72%), and final mean logMAR (1.88±0.76) was significantly lower (P<0.01). Five eyes with myopic CNV maintained their visual acuity (VA) from before operation (mean logMAR, 0.88±0.35) until final follow-up (mean logMAR, 0.73±0.31).
Introduction
Age-related macular degeneration (AMD) is the leading cause of legal blindness among the elderly in industrialized countries 1 , and there has been a recent trend for the number of such patients to increase in Japan 2 . Full macular translocation has been performed to treat exudative AMD 3 . Recently, however, the main treatments for choroidal neovascularization (CNV), including exudative AMD, have become anti-vascular endothelial growth factor (VEGF) therapy 4 and photodynamic therapy (PDT) 5 , because long-term follow-up has shown that macular translocation is not effective 6 and has a high rate of postoperative complications, such as proliferative vitreoretinopathy and retinal detachment.
Most studies have reported a favorable outcome with 2 years of follow-up after full macular translocation [7] [8] [9] [10] [11] [12] . On the other hand, there are a few reports with follow-up of 3 years or longer, and their results were poor 6 . In this report, the long-term results (at least 5 years of follow-up) are reported for patients who underwent full macular translocation.
Methods
Full macular translocation was performed for CNV in 45 eyes of 45 patients from November 1999 to June 2002 at Nagasaki University. This study involved 32 eyes of 4 32 patients with follow-up of 5 years or longer. CNV was classified, and CNV lesion sizes were measured by fluorescein angiography preoperatively 13 . The best corrected visual acuity (BCVA), fundus examinations before, 1 year, and 5 years after operation, and postoperative complications were reviewed retrospectively using the patients' clinical records.
Surgical technique: The surgical procedure included phacoemulsification and implantation of an intraocular lens (IOL) in phakic eyes. Then, three-port pars plana vitrectomy was performed, posterior vitreous detachment was induced, and the vitrectomy was completed to the vitreous base. Balanced saline solution was injected to induce total retinal detachment, and 360° retinotomy was performed at the posterior edge of the vitreous base. Then, CNV was removed, a small amount of perfluorocarbon liquid was injected onto the retinal surface, and the retina was rotated in order to move the fovea to the normal area of retinal pigment epithelium (RPE). Perfluorocarbon liquid was added up to the edge of the retinotomy site, and peripheral laser retinopexy was performed at the edge of the retinotomy sites in all quadrants after retinal re-attachment. Silicone oil tamponade was performed at the end of the procedure. The mean duration of silicone oil tamponade was 5 months.
Statistical analysis: Results are expressed as means±standard deviation.
Analysis of variance with Tukey's test was used to compare BCVA before and after 5 operation. Multiple regression analysis was used to evaluate final BCVA, which is known to be related to age, etiology of CNV (AMD, myopic), and preoperative BCVA.
Logistic regression analysis was used to evaluate the relationships between CNV recurrences and age, sex, etiology of CNV (AMD, myopic), type of CNV (classic, occult), lesion size, preoperative BCVA, final BCVA, and tobacco use. Statistical analysis was performed using Statflex ver. 5.0 software.
Results
The study included 32 eyes of 32 patients (8 females, 24 males; mean age at operation, 66.6 years) that underwent full macular translocation. All patients were Japanese. The causes of CNV were exudative AMD in 25 eyes, myopic in 5 eyes, idiopathic in 1 eye, and angioid streaks in 1 eye. The mean duration of follow-up was (Table 1) . VA was worse in the abnormal fovea group than in the normal fovea group 5 years or longer after operation, but the difference was not statistically significant (p=0.051). In the 4 eyes with a normal fovea at 5 years, VA was good in 3 eyes, but progressive visual loss due to an unknown cause occurred in 1 eye. At the final observation, VA was worse than before operation in 18 eyes (72%), there were no changes in 3 eyes (12%), and 8 VA was improved in 4 eyes (16%).
In the myopic CNV group, there were 3 female and 2 male patients, with a mean age at operation of 51.0 years (Table 1) Table 1) .
On multiple regression analysis, the final VA was better in myopic CNV than in exudative AMD (p=0.019). Logistic regression analysis showed that there were no significant differences in characteristics (age, sex, etiology of CNV, type of CNV, lesion size, preoperative VA, final VA, and tobacco use) between patients with CNV recurrence and those without CNV recurrence. 9 
Discussion
Many cases of full macular translocation for exudative AMD have been reported [6] [7] [8] [9] [10] . However, most of these reported the results of follow-up of up to only 2 years 7-10 , while only a few reported long-term follow-up results 6 The most common cause of visual loss was RPE atrophy in the new fovea, which advanced slowly in the present study. RPE atrophy spread from the original fovea to the new one in these cases. The natural history of the VA in patients with exudative AMD is poor with no therapy, and we often found that RPE atrophy spread widely in patients with low activity CNV. The choroidal abnormal vessel network is often large, and RPE function in this area is considered to be low. Therefore, the new fovea would sometimes become atrophic if the original fovea was moved over the seemingly normal RPE. There was an interesting report that RPE geographic atrophy had spread rapidly after full macular translocation for atrophic AMD 14 . RPE cell implantation has been tried for RPE atrophy, but it did not achieve good results 15 . The other possible reason for RPE atrophy was RPE damage by CNV removal or artificial retinal detachment. However, the cause was unknown, because RPE atrophy did not develop immediately after the operation, and RPE atrophy did not always develop in the macular area in rhegmatogenous retinal detachment.
Long-term visual acuity was relatively better in full macular translocation for myopic CNV in the present study. Glacet-Bernard et al. compared the results of limited macular translocation for AMD and myopic CNV with follow-up of nearly 9 months 16 . The improvement in visual acuity was better in the myopic group than in the AMD group, and they considered that the prognosis for VA was affected by the smaller foveal displacement, the lower rate of recurrence and retinal detachment, and the younger age in the myopic group. The only prognostic factor for better VA after macular translocation was younger age in the myopic group in the present study, which is similar to the report by Glacet-Bernard et al.
It has been reported that the average VA was stable for 2 to 5 years after a single PDT treatment, but decreasing VA was found in 35% of cases 5 . On the other hand, decreasing VA (3 or more lines decrease) was found in 14 eyes (56%) 5 years or longer after full macular translocation in AMD in this study. Therefore, VA with full macular translocation was worse than with a single PDT treatment 5 years after treatment. However, treatments for AMD were not simply compared because of the different populations and different types of AMD. We performed full macular translocation for CNV cases with very poor VA, such as 1.0 (logMAR) or worse, and with very wide degenerative lesions. Gelisken et al. suggested that full macular translocation should not be offered as a standard primary procedure for AMD because the era of anti-VEGF therapy would come, even though the chance for vision improvement was significantly higher in the full macular translocation group than in the PDT group 1 year after treatment in their study 17 . It has been reported that VA with a single anti-VEGF treatment was better than that without therapy 2 years after treatment 4 . In many reports, the current main treatment for CNV is combined PDT and anti-VEGF therapy or triamcinolone acetonide 18, 19 . It is necessary to consider the long-term follow-up results of such therapy.
In conclusion, full macular translocation for exudative AMD has a poor prognosis, but selected cases of myopic CNV with foveal fibrosis or high activity in which PDT 20 or anti-VEGF therapy is ineffective may benefit from full macular 
